NO933860L - Ekstracellulære matriks-reseptorligander som modulerer leukocyttfunksjon - Google Patents

Ekstracellulære matriks-reseptorligander som modulerer leukocyttfunksjon

Info

Publication number
NO933860L
NO933860L NO933860A NO933860A NO933860L NO 933860 L NO933860 L NO 933860L NO 933860 A NO933860 A NO 933860A NO 933860 A NO933860 A NO 933860A NO 933860 L NO933860 L NO 933860L
Authority
NO
Norway
Prior art keywords
extracellular matrix
receptor ligands
leukocyte function
lymphocyte
soluble
Prior art date
Application number
NO933860A
Other languages
English (en)
Other versions
NO933860D0 (no
Inventor
Alejandro A Aruffo
N Jan Chalupny
John Marken
Jeffrey A Ledbetter
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO933860D0 publication Critical patent/NO933860D0/no
Publication of NO933860L publication Critical patent/NO933860L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Abstract

Det omtales et løselig fusjonsmolekyl som inneholder leukocyttreseptorers ekstracellulaere bindingsregion, og som er i stand til å bindes til ekstracellulaere matrise- assosierte proteiner. De beskrevne lymfocytt- til - ligand proteiner inkluderer løselige fusjonsmolekyler av 4-1BB, CD27, CD30, FÅS, TNF-reseptor og CD40. Anvendelse av et løselig lymfocyttligandprotein til modulering av leuko- cyttfunksjon hvor en løselig lymfocytt mellom leukocytt- reseptorer og et målvevs ekstracellulaere matriksforbundne protein er omtalt.
NO933860A 1992-10-30 1993-10-27 Ekstracellulære matriks-reseptorligander som modulerer leukocyttfunksjon NO933860L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96970092A 1992-10-30 1992-10-30

Publications (2)

Publication Number Publication Date
NO933860D0 NO933860D0 (no) 1993-10-27
NO933860L true NO933860L (no) 1994-05-02

Family

ID=25515876

Family Applications (1)

Application Number Title Priority Date Filing Date
NO933860A NO933860L (no) 1992-10-30 1993-10-27 Ekstracellulære matriks-reseptorligander som modulerer leukocyttfunksjon

Country Status (8)

Country Link
EP (1) EP0595659A3 (no)
JP (1) JPH072899A (no)
AU (1) AU5034493A (no)
CA (1) CA2109398A1 (no)
FI (1) FI934751A (no)
IL (1) IL107432A0 (no)
MX (1) MX9306682A (no)
NO (1) NO933860L (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5246113A (en) * 1992-02-11 1993-09-21 Riverwood International Corporation Carrier for stacked articles
US5683693A (en) 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
IL129138A0 (en) 1996-10-11 2000-02-17 Bristol Myers Squibb Co Methods and compositions for immunomodulation
AU1288099A (en) * 1997-10-30 1999-05-24 Cornell Research Foundation Inc. A method of inhibiting an immune response to a recombinant vector
AU2007341631B9 (en) 2006-12-28 2012-10-04 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo
RU2652348C2 (ru) 2012-07-18 2018-04-25 Аподжиникс Аг Ингибиторы сигнального пути cd95 для лечения мдс
JP2014184804A (ja) 2013-03-22 2014-10-02 Toyota Motor Corp 車両用動力伝達装置の制御装置
EP3076179A1 (en) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
US20180244792A1 (en) * 2015-09-10 2018-08-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Anti-fibrotic effect of cd70
BR112021019328A2 (pt) 2019-03-29 2021-11-30 Myst Therapeutics Llc Métodos ex vivo para produzir um produto terapêutico de célula t e composições e métodos relacionados
CA3162703A1 (en) 2019-11-27 2021-06-03 Myst Therapeutics, Llc Method of producing tumor-reactive t cell composition using modulatory agents
MX2022010517A (es) 2020-02-27 2022-11-14 Myst Therapeutics Llc Metodos para la expansion y enriquecimiento ex vivo de celulas t reactivas a tumor y composiciones relacionadas de las mismas.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3149289A (en) * 1988-03-18 1989-09-21 Rockefeller University, The Method and agent for inhibiting the binding of human polymorphonuclear leukocytes to endothelium and compositions therefor
US5057604A (en) * 1988-08-03 1991-10-15 Washington University Novel monoclonal antibodies
US5204445A (en) * 1988-10-03 1993-04-20 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5169930A (en) * 1990-01-05 1992-12-08 La Jolla Cancer Research Foundation Fibronectin receptor
WO1991019511A1 (en) * 1990-06-18 1991-12-26 The General Hospital Corporation CONTROLLING CELLULAR IMMUNE/INFLAMMATORY RESPONSES WITH β2 INTEGRINS

Also Published As

Publication number Publication date
CA2109398A1 (en) 1994-05-01
NO933860D0 (no) 1993-10-27
IL107432A0 (en) 1994-01-25
EP0595659A2 (en) 1994-05-04
FI934751A0 (fi) 1993-10-27
EP0595659A3 (en) 1995-01-11
FI934751A (fi) 1994-05-01
AU5034493A (en) 1994-05-12
MX9306682A (es) 1994-04-29
JPH072899A (ja) 1995-01-06

Similar Documents

Publication Publication Date Title
NO933860L (no) Ekstracellulære matriks-reseptorligander som modulerer leukocyttfunksjon
DE69334129D1 (de) Modulierung der TNF-Rezeptoraktivität
WO1993023550A3 (en) Activation of oligomerizing receptors by using fused receptor ligands
IL114615A0 (en) Modulators of the function of fas receptors and other proteins
ATE247667T1 (de) Gdnf-rezeptor und dessen verwendung
EP0835447A4 (en) PEPTIDES AND COMPOSITIONS THAT MODULE THE APOPTOSIS.
IL217265A0 (en) Use of transmembrane activator, calcium modulator and taci-immunoglobulin fusion proteins for manufacture of a medicament for treating sjogren's syndroem
ES2229045T3 (es) Derivados de peptidos terapeuticos.
BR0011342A (pt) Métodos para a modulação de diabetes tipo 2, para modular a resistência à insulina, para alìvio de hiperlipidemia e para tratamento de hiperuricemia em um mamìfero, e, composição farmacêutica
CA2217169A1 (en) Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
FI113341B (fi) Menetelmä vaikuttavaa ainetta sisältävä laastarin valmistamiseksi alhaisessa lämpötilassa sulaville ja/tai haihtuville vaikuttaville aineille
BR9708518A (pt) Moduladores de fator associado a receptor tnf (traf) sua preparação e uso
BG109537A (en) FUNCTION MODULATORS OF RECEPTORS OF TNF / NGF RECIPE FAMILY AND OTHER PROTEINS
ATE207459T1 (de) O-malonyltyrosyl-verbindungen, o-malonyltyrosyl- verbindungen enthaltende peptide und ihre verwendung
DK0760851T3 (da) Tumor-nekrose-faktor receptor-associeret-faktor
WO2002024222A3 (en) Ligands for g protein coupled receptors and methods of using them
NZ514091A (en) Vascular adhesion molecules and modulation of their function
WO1998032017A3 (en) Modulators of insulin receptor activity
DK0752991T3 (da) Indeno[1,2-e]pyrazin-4-oner, fremstilling af disse forbindelser og lægemidler indeholdende disse forbindelser
WO2000001820A3 (en) Nucleic acid molecules encoding nuclear hormone receptor coactivators, and uses thereof
WO2003062276A3 (en) Multimers of receptor-binding ligands
AU3878889A (en) Irreversible peptide ligands for bombesin receptors
AU2002228924A1 (en) Modulators of activity of g-protein-coupled receptor kinases
Cha et al. Specificity of molecular recognition learned from the crystal structures of TRAIL and the TRAIL: sDR5 complex
MX9705624A (es) Ligandos para receptores similares al eph.